Healthcare distributor Cencora (NYSE: COR) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 10.3% year on year to $75.45 billion. Its non-GAAP profit of $4.42 per share was 7.9% above analysts’ consensus estimates.

Is now the time to buy COR? Find out in our full research report (it’s free).

StockStory’s Take

Cencora’s first quarter results were shaped by broad-based strength in its U.S. Healthcare Solutions segment, with management attributing growth to rising demand for specialty medications and higher utilization across health systems and specialty physician practices. CEO Bob Mauch highlighted the company’s investments in end-to-end pharmaceutical services and deepening partnerships with providers as pivotal to this performance. The recent integration of Retina Consultants of America (RCA) was cited as a key contributor to gross profit margin expansion, with CFO Jim Cleary noting, “RCA does add meaningfully to gross profit margin and operating margin… it is a higher-margin business than our core distribution business.” Management also pointed to ongoing productivity initiatives and a smaller-than-expected COVID-19 headwind as supporting factors.

Looking ahead, Cencora’s outlook is informed by its positioning in specialty pharmaceuticals, expectations for continued growth in the U.S. market, and ongoing integration of recent acquisitions. Management anticipates slower revenue growth in the second half of the year, citing tougher comparisons for GLP-1 products and biosimilar competition in mail-order channels. CFO Jim Cleary explained, “We anticipate our growth will be at the bottom end of the respective ranges,” reflecting these headwinds but also suggesting potential margin benefits from product mix shifts. The company remains focused on expanding value-added services, strengthening specialty offerings across sites of care, and leveraging its data-driven insights to support both biopharma partners and healthcare providers.

Key Insights from Management’s Remarks

Management cited several operational and strategic developments as primary drivers of both quarterly results and the company’s evolving competitive positioning.

• Specialty segment momentum: The company’s specialty business, including physician practices and health systems, drove broad-based growth, supported by continued investments in services and wraparound offerings such as group purchasing organizations (GPOs) and management service organizations (MSOs).
• RCA integration impact: The acquisition of Retina Consultants of America contributed to margin expansion due to its higher profitability profile compared to Cencora’s core distribution operations. The accounting treatment of RCA’s minority interest also resulted in a higher-than-expected EPS contribution.
• GLP-1 product dynamics: GLP-1 (glucagon-like peptide-1) medications remained a significant revenue driver, though management noted a sequential decline from the prior quarter and minimal profit contribution. The company expects GLP-1 growth rates to moderate in upcoming quarters.
• International market softness: The International Healthcare Solutions segment experienced subdued demand, particularly in global specialty logistics and consulting related to clinical trials. Management described this as a market-wide issue and adjusted guidance downward to reflect slow recovery in these areas.
• Broad-based provider growth: Cencora reported growth across its specialty provider verticals, including oncology and retina, with management emphasizing robust positioning across community practices and health systems rather than concentration in any single sub-segment.

Drivers of Future Performance

Cencora’s forward outlook is shaped by shifting specialty drug dynamics, international market uncertainty, and continued strategic investments in higher-margin services.

• Specialty and biosimilar expansion: Management expects specialty pharmaceuticals and biosimilars to remain key growth drivers, with continued investment in value-added services for both biopharma manufacturers and provider partners. The company’s MSO and GPO offerings are designed to deepen relationships and capture a greater share of specialty market growth.
• International segment headwinds: The company anticipates ongoing weakness in its International Healthcare Solutions segment due to soft clinical trial activity and slower-than-expected recovery in global specialty logistics. Management revised down operating income expectations for this segment, citing industry-wide delays in clinical trial starts and subdued demand for consulting services.
• Product mix and margin effects: Shifts toward higher-margin specialty products and reduced contribution from lower-margin high-priced mail-order products are expected to benefit consolidated operating margins, partially offsetting slower top-line growth. Management noted that these mix effects will likely drive operating income growth above revenue growth, especially in the U.S. segment.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team will monitor (1) U.S. specialty drug utilization trends and the pace of biosimilar adoption, (2) the trajectory of international clinical trial activity and any signs of a rebound in specialty logistics, and (3) further integration milestones for RCA and the expansion of high-margin MSO services. The evolution of tariff policy and its potential effects on pharmaceutical supply chains will also be an important area for scrutiny.

Cencora currently trades at a forward P/E ratio of 17.6×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.